Edition:
India

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

27.95USD
23 Feb 2018
Change (% chg)

$0.91 (+3.37%)
Prev Close
$27.04
Open
$27.10
Day's High
$28.00
Day's Low
$26.50
Volume
69,582
Avg. Vol
68,203
52-wk High
$43.30
52-wk Low
$22.94

Select another date:

Mon, Jan 29 2018

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

BRIEF-Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​

* THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA

BRIEF-Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD

* Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD Source text for Eikon: Further company coverage:

BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin

* Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease

BRIEF-Theravance Biopharma posts Q3 loss of $1.27 per share

* Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update

BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin

* Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting

BRIEF-Theravance Biopharma reports positive new data from multiple studies of VIBATIV at IDWeek 2017

* Theravance Biopharma reports positive new data from multiple studies of VIBATIV (telavancin) at IDWeek 2017

BRIEF-Theravance Biopharma highlights positive results from impact study of Trelegy Ellipta

* Theravance Biopharma highlights positive headline results from impact study of Trelegy Ellipta announced by Glaxosmithkline and Innoviva

BRIEF-Theravance Biopharma highlights approval of trelegy ellipta for treatment of appropriate patients with COPD in the U.S.

* Theravance Biopharma highlights approval of trelegy ellipta (closed triple) as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US

Select another date: